Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic
  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q1 2024 Financial, Operational Report

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, is reporting on its financial and operational results for first quarter 2024, for the period ended March 31, 2024. Highlights of the report include the 510(k) submission for BEAT’s AIMIGo(TM) system for review by the U.S. Food and Drug Administration (“FDA”); presubmission meetings being held with the FDA in preparation to submit a second 510(k) for BEAT’s 12-lead synthesis software; beginning patient enrollment for a study designed to demonstrate the similarity between the synthesized 12-lead ECG and a standard 12-lead ECG; the presentation of key data at the European Heart Rhythm Association (“EHRA”) conference; and receiving two new patents on ambulatory VECG technology from the U.S. Patent and Trademark Office. Notable financial numbers from the report include R&D expenses for the quarter totaled $2.4 million, compared to $1.7 million for Q1 2023; general and administrative expenses for the quarter totaled $2.4 million compared to $2.5 million for Q1 2023; net loss for the quarter was $4.6 million; and cash and cash equivalents totaled $12.6 million as of March 31, 2024. “In the first quarter we remained on track with expected regulatory and clinical milestones for the AIMIGo 3D VECG technology platform, and in tandem advanced developments related to the use of artificial intelligence (‘AI’) applied to our VECG technology,” said HeartBeam founder and CEO Branislav Vajdic, PhD, in the press release. “Following the FDA 510(k) submission for the AIMIGo VECG system, we currently anticipate clearance by the end of Q2 2024, and a limited launch of AIMIGo by the end of 2024. . . . In April we presented positive new data for our deep learning algorithm, HeartBeam AI, at the EHRA conference. The study shows that HeartBeam AI combined with VCG delivers equivalent performance to a 12-lead ECG and greatly improves detection of atrial flutter over a single-lead ECG. We believe this presents an opportunity for a VCG-based algorithm that offers arrhythmia detection capabilities beyond what is available today and to make it easier to obtain a 12-lead ECG.”

To view the full press release, visit https://ibn.fm/muQHe

About HeartBeam Inc.

HeartBeam is a medical technology company dedicated to transforming cardiac care through the power of personalized insights. The company’s proprietary vectorelectrocardiography (“VECG”) technology collects 3D signals of the heart’s electrical activity and converts those signals into a 12-lead ECG. This platform technology is designed to be used on portable, patient-friendly devices such as a credit-card-sized monitor, watch or patch. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care, all outside of a medical facility, thus redefining how cardiac health is managed. For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.